Raymond James Financial
VIR icon

Raymond James Financial’s Vir Biotechnology VIR Stock Holding History

Raymond James Financial’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Buy
42,571
+30,238
+245% +$288K ﹤0.01% 4609
2026
Q1 		$111K Buy
+12,333
New +$98.3K ﹤0.01% 5013
2025
Q3 		– Sell
-7,018
Closed -$35.4K – 6727
2025
Q2 		$35.4K Buy
+7,018
New +$37.6K ﹤0.01% 5321

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Raymond James Financial's VIR Position: Q2 2026 in Review

Raymond James Financial increased its Vir Biotechnology (VIR) stake by 245% in Q2 2026, buying an estimated $288K and bringing the position to 42,571 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #4609.

Raymond James Financial first reported a position in VIR in Q2 2025 and has held it in 3 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Raymond James Financial held 42,571 shares of Vir Biotechnology worth $434K as of Q2 2026.
  • Raymond James Financial bought 30,238 Vir Biotechnology shares in Q2 2026, an estimated $288K.
  • Vir Biotechnology made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4609 holding.
  • Raymond James Financial first reported a position in Vir Biotechnology in Q2 2025 and has held it in 3 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.